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Although there has been a decrease in cardiovascular disease mortality across higher 
income countries, huge inequalities persist with cardiovascular disease accounting for 
more than 50% of all deaths in many middle-income countries compared with less than 
30% in the high-income countries of Western Europe [1]. Accounting valvular heart 
diseases (VHD) for a significant part of cardiovascular disease, after hypertension and 
coronary artery disease (CAD). In industrialized countries, the prevalence of valvular heart 
diseases is estimated at 2.5% and, because of the predominance of degenerative 
etiologies, the prevalence of valvular disease increases markedly after the age of 65 years 
[2], from 0.7% in 18-44 years of age to 13.3% in the 75 years and older groups [3]. Thus, 
with the ageing of the population and with the use of better diagnostic tools, calcific aortic 
stenosis (AS) has become the most common primary valve disease leading to surgery or 
catheter intervention in Europe and North America, with a growing prevalence in the 
general population [3]. In most European countries moderate aortic stenosis is present in 
5% of the population over the age of 75 and severe AS in 3%. 
Precise molecular mechanisms involved in the pathophysiology underlying calcific aortic 
stenosis are still lacking. As has been well described [4, 5], for the normal function of the 
aortic valve, the leaflets must be both strong and flexible to withstand the considerable 
mechanical stress and strain associated with valve function. The cusp microarchitecture is 
crucial and consists of three layers: fibrosa, spongiosa, and ventricularis. Valvular 
endothelial cells (VEC) are located at valvular surfaces, constituting a barrier that 
regulates valve permeability, the adhesion of inflammatory cells and paracrine and 
systemic signaling. Valvular interstitial cells (VIC), the major cell type, are present 




regulating both the synthesis and degradation of extracellular matrix components. 
Physiologically, Valvular interstitial cells exist in a quiescent state, with similar 
characteristics to fibroblasts. Stimulation of VECs and VICs by molecular and mechanical 
triggers including high blood pressure, altered shear stress, cytokines, and growth factors 
contributes to aortic stenosis pathophysiology, altering the local valve environment and 
activating the calcification process. Indeed, nowadays calcific aortic valve stenosis is 
viewed as a fibrocalcific disease; triggered in areas of the valve with altered flow patterns, 
increased mechanical stress, and reduced shear stress, which causes endothelial damage 
and activation [4]. This initial phase shows similarities with atherosclerosis and shares 
common risk factors including age, male gender, body mass index, smoking, 
hypertension, and altered lipid metabolism [6]. During this initiation phase mechanical 
stress, endothelial damage, inflammation, and lipid deposition play the main role in calcific 
aortic stenosis pathophysiology. As mentioned, the first event is believed to be endothelial 
damage resulting from increased mechanical stress and reduced shear stress [7]. Shear 
stress is highest in the cusps adjacent to the coronary ostia because of the influence of 
coronary artery flow. Consequently, the non-coronary cusp has lower shear stress and is 
most frequently involved in aortic stenosis. Mechanical tissue stress is highest around the 
flexion areas of the cusps near their attachment to the aortic root, being a frequent region 
where aortic valve lesions are observed [8]. Endothelial disruption may allow inflammatory 
cells to penetrate the valvular endothelium activating forwarded steps of a cascade that 
favors the accumulation of lipids in these areas of inflammation, including low-density 
lipoprotein and lipoprotein(a), which undergo oxidative modification being then highly 
cytotoxic and capable of stimulating more inflammatory activity and subsequent 
mineralization [9, 10]. This initial pathophysiological phase of inflammation is supported by 
studies demonstrating increased systemic C-reactive protein concentrations, a marker of 




imaging studies, which used the combination of positron emission tomography and 
computed tomography with Fluorine-18 fluorodeoxyglucose (18F-FDG) as a marker of 
macrophage activity. Increased 18F-FDG levels have been described in patients with 
aortic stenosis compared with controls, displaying a progressive rise in activity with 
increasing valve severity [12]. After this initial phase of inflammation and lipid deposition, 
in a second described pathophysiological phase of progressive valve narrowing, local 
fibrosis and calcification become overwhelming, ultimately leading to severe calcification 
and valvular dysfunction. The stenotic aortic valve is characterized by extensive thickening 
due to the accumulation of fibrous tissue and remodeling of the extracellular matrix. 
Abundant fibroblast-like cells are found in the aortic valve leaflets, and a subpopulation of 
these cells become activated during the inflammatory activity and differentiate into 
myofibroblasts, which are believed to play an important role in the accelerated fibrosis 
observed in aortic stenosis [13]. The renin-angiotensin system is thought to have the 
potential to modify this fibrotic process [14]. Finally, aortic valve calcification becomes 
crucial in the pathophysiology of aortic stenosis, leading to valve narrowing and stenosis. 
Disorders of mineral metabolism, including Paget disease, osteoporosis, vitamin D 
polymorphisms, and hemodialysis, are all associated with an increased prevalence of 
aortic stenosis. Interestingly, microscopic areas of calcification can be observed in the 
early stages of aortic sclerosis, co-localizing areas of inflammation and lipid deposition [15, 
16]. This progression is thought to be driven by the differentiation of myofibroblasts into 
osteoblasts under the influence of different signaling pathways. Osteoblasts subsequently 
coordinate calcification as part of a complex process finally facilitating new bone formation 
[17]. Continued remodeling of these calcification areas occurs during the progress to 
severe calcific aortic stenosis [18]. Combined positron emission tomographic and 
computed tomographic imaging has confirmed the pathogenic role of calcification in aortic 




hydroxyapatite crystal having the potential to detect areas of calcification under 
development and or remodeling. Uptake of 18F sodium fluoride is increased within 
stenotic aortic valves compared with control subjects, displaying a progressive rise in 
activity with increasing disease severity [12]. All these data add further support to 
calcification as an important process in the pathogenesis of aortic valve narrowing during 
this second propagation phase of the disease. 
Thus, calcific aortic stenosis is a gradually progressive disease, characterized by a long 
asymptomatic period lasting several decades with inflammation and progressive fibro-
calcification of the aortic valve, followed by a shorter symptomatic phase associated with 
severe or “critical” narrowing of the orifice of the aortic valve. Once symptoms occur, 
patient survival is markedly limited, expressing an end stage of the disease with 
sometimes even rapidly exponential progression from mild exertional to advanced heart 
failure symptoms. 
Despite growing knowledge, experience, and technological developments, the only 
treatment for severe aortic stenosis is surgical or trans-catheter aortic valve replacement 
(AVR). In the last decade multiple observational pharmacological studies and randomized 
controlled trials acting in different pathophysiological pathways attempted to demonstrate 
a reduction of the progression to surgery of calcific aortic stenosis. Statins are widely used 
for lipid lowering in atherosclerosis, being a specific inhibitor of 
hydroxymethylglutarylcoenzyme A-reductase (HMG-CoA-reductase) with also anti-
inflammatory effects. With the hypothesis of reduction of lipid deposition in the aortic valve 
leaflets and less VIC’s activation due to anti-inflammatory effects, retrospective studies 
suggested that statins might be of benefit in calcific aortic stenosis [19-23]. But, 
subsequent randomized controlled trials demonstrated that statins in fact have no 




Angiotensin-converting enzyme (ACE) inhibitors and angiotensin receptor blockers (ARBs) 
are well-known attenuators of the cascade renin–angiotensin-aldosterone, which has been 
associated with the fibrocalcific pathophysiological pathway of aortic stenosis [4]. In 
patients with calcific AS, one randomized trial has shown a modest but significant 
reduction of myocardial hypertrophy in patients treated with ramipril [25], and one clinical 
observational study has suggested that ACE inhibitors and ARBs are associated with 
favorable effects on symptoms (dyspnea and exercise tolerance) and improved survival 
[26]. But, although, some observational retrospective studies, investigating the effect of 
ACE inhibitor and ARBs on aortic stenosis progression, were associated with less valve 
fibrosis and calcification [27, 28], there is still conflicting data [23] and most importantly 
prospective randomized controlled trials are lacking on this topic. Thus, pharmacological 
interventions until now have failed to alter the course of calcific aortic stenosis. 
Therefore, guidelines [29, 30] still advocate aortic valve replacement for patients with 
severe aortic stenosis in the presence of either: (A) classical symptoms (angina, syncope, 
or exertional dyspnea); or (B) left ventricular (LV) systolic dysfunction (i.e. LV ejection 
fraction <50%). Being the results of surgical AVR for acquired aortic stenosis a medical 
advantage of the last decades. Age-corrected survival after aortic valve replacement is 
excellent for patients over the age of 65 years and is similar to that of the normal 
population of that age [31]. In the absence of extracardiac co-morbidities and in the 
absence of coronary artery disease, aortic valve replacement can be performed at a 2% to 
3% operative mortality with an 85% age-corrected 10-year survival. This excellent 
outcome can be attributed to a variety of factors including the universal use of 
intraoperative cardiac protection, the insertion of hemodynamically excellent and durable 
valve prostheses, but also a proper “timing” of aortic valve replacement. Nowadays, there 




patients with valvular heart disease in high-specialized heart centres, being the main 
purpose of these heart valve centres as centres of excellence in the treatment of valvular 
heart disease to deliver better quality of care. This is achieved through greater volumes 
associated with specialization of training, continuing education and clinical interest. In this 
way, specialization will also result in timely referral of patients before “irreversible” adverse 
effects occur in patients with valvular heart disease conditions. Indeed, the presence of 
“advanced” heart failure symptoms in patients with aortic stenosis is associated with worse 
outcomes and also with persistence of symptoms after successful aortic valve replacement 
[32, 33], giving evidence of the participation of other factors rather than the solely 
presence of aortic valve narrowing. Being of crucial importance the identification of these 
factors, to avoid the referral of patients to aortic valve replacement with a predisposition to 
have worse postoperative outcomes and persistence of heart failure, which also means 
higher healthcare costs. 
Classically, aortic stenosis has been seen as a solely progressive calcification of the aortic 
valve that causes a gradual reduction in valve area leading to a “critical stenosis”, which 
theoretically triggers the typical aortic stenosis related symptoms. As have been proposed 
the definition of “critical aortic stenosis” should be that valve area small enough to cause 
the symptoms of aortic stenosis: a “critical” situation predicting aortic valve replacement. 
But, this “critical aortic valve area” seems to be not a single fixed value but a continuous 
range [34], in fact, this “critical” zone varies from patient to patient. As Otto and colleagues 
[35] pointed out, patients who are symptomatic but have a valve area >1.0 cm2 probably 
have symptoms based on another extravalvular problem. Patients with a valve area of 
<0.8 cm2 who have typical symptoms almost certainly have them on the basis of aortic 
valve stenosis. And patients with areas ranging from 0.8 to 1.0 cm2 are in the gray zone in 




no longer considered a passive consequence of ageing but an active process involving 
cellular and multiple molecular pathways. Dweck and colleges revived the concept of 
calcific aortic stenosis as a disease of the valve and myocardium [7]. Aortic stenosis 
causes an increase in pressure afterload and ventricular wall stress that stimulates 
hypertrophy of the left ventricular myocardium. Myocytes enlarge and wall thickness 
increases in a response that initially restores wall stress and preserves left ventricular 
function [36]. But, an inappropriately high left ventricular hypertrophy has been 
demonstrated to be associated with worse prognosis [37]. In calcific aortic stenosis, 
patients display a marked variation in the magnitude of their hypertrophic response. The 
mechanisms involved in left ventricular hypertrophy in patients with aortic stenosis should 
then be more than a simple response to mechanical forces, explaining the marked 
heterogeneity between symptom onset and the severity of valve narrowing that is 
observed (i.e. gray zone of aortic valve area between 0.8 and 1.0 cm2). The resulting LV 
structural changes (i.e. progressive myocardial fibrosis and stiffness [38]) may gradually 
cause diastolic and, at a later stage, systolic dysfunction [39]. The precise mechanisms 
behind this transition from adaptive to maladaptive LV hypertrophy are poorly defined but 
involve myocardial damage and are not directly related with the severity of valve narrowing 
[40]. The maladaptive response of the LV involves programmed cell death or apoptosis’s 
pathways and remodeling of the extracellular matrix with deposition of interstitial collagen, 
leading to myocardial fibrosis and increased myocardial wall stiffness [41]. These 
pathophysiological pathways seem to run parallel to the progression of the aortic valve 
disease, and are influenced from multiple factors explaining the heterogeneous response 
between two different patients with similar aortic stenosis severity. Several studies aimed 
to evaluate diagnostic methods for early detection of LV interstitial fibrosis in patients with 
aortic stenosis before any signs of impaired cardiac function become apparent. 




longitudinal peak systolic strain (speckle tracking) or the mitral annular plane systolic 
excursion (M-mode). They were able to demonstrate LV myocardial involvement despite 
preserved LV ejection fraction, and also were predictors of symptoms onset in patients 
with asymptomatic aortic stenosis. Using T1 mapping techniques, with histology validated 
cardiac magnetic resonance studies detected diffuse myocardial fibrosis even after 
extended focal fibrosis was present, and also showed prognostic significance, but still 
there seems to be a huge overlap when compared with elderly population without aortic 
valve disease. And finally there are several biomarkers of myocardial fibrosis pathway’s 
activity under investigation (transforming growth factor β1, collagen-derived peptides, 
matrix metalloproteinases, micro RNAs, etc) [42]. Anyhow, a disproportionate or more 
marked LV remodeling in patients with aortic stenosis may clinically translate into onset of 
advanced symptoms and increased risk for potential permanent left ventricle dysfunction 
and adverse cardiovascular events. 
Indeed, not only parameters expressing a valve narrowing (i.e. valve area, peak velocity, 
and gradients) but also those associated with involvement of the left ventricle (i.e. left 
ventricle ejection fraction, hypertrophy, reduced LV global longitudinal peak systolic strain, 
etc.) have been associated with the development of symptoms in the course of aortic 
stenosis progression. Thus, it can be argued, that once aortic stenosis is severe, the 
“onset” of symptoms and more importantly the severity of them depend on a combination 
of aortic valve narrowing with multiple other linked factors, such as the association with 
comorbidities (i.e. hypertension, diabetes, coronary artery disease, etc.), age, male 
gender, and left ventricle myocardial remodeling. 
Moreover, it has been demonstrated that the cardiac structural and functional alterations 
are associated not only with the development of symptoms [43, 44], but also with the type 




smaller left ventricle dimension, stroke volume, and left atrial volume index, and patients 
with dyspnea had the worst diastolic function with largest left atrial volume index and 
highest E/e’ ratio; while having a similar aortic valve area and gradient.  
However, it has never been investigated which clinical and echocardiographic 
characteristics are associated with the presence of “advanced” symptoms in patients with 
severe aortic stenosis referred for aortic valve replacement. It remains to be determined, 
whether advanced symptoms in patients with severe aortic stenosis are associated solely 
with aortic valve narrowing or also with other factors. It is more likely that multiple factors 
are playing a role in the pathogenesis of severe aortic stenosis. There are endless 
possible pathways influencing and or aggravating the afterload imposed on left ventricle by 
an aortic valve narrowing. For instance a more pronounced local inflammatory response, 
which could disseminate systemically through paracrine and systemic signaling activating 
fibrosis and apoptosis pathways in distal areas leading to earlier and more pronounced 
myocardial damage. Phenomenon that may get enhanced in association with 
comorbidities, triggering heart failure symptoms in an earlier phase of aortic valve 
calcification and narrowing with valve areas in the gray zone of 0.8 to 1.0 cm2. 
Hence, we aimed to describe the relationship between the presence of “advanced” 
symptoms and the clinical and echocardiographic characteristics of a cohort of patients 
with severe aortic stenosis referred for aortic valve replacement. Biomarkers of 
inflammation (C-reactive protein), of cardiovascular stress (NT-pro-B-type natriuretic 




Advanced symptoms are associated with myocardial damage in
patients with severe aortic stenosis
Ricardo A. Spampinato (MD)a,*, Manuela Tasca (MD)a, Michael A. Borger (MD, PhD)b,
Valerie Schloma (MD)a, Yaroslava Dmitrieva (MD)a, Meinhard Mende (PhD)c,
Thilo Noack (MD)a, Elfriede Strotdrees (MD)a, Friedrich-W. Mohr (MD, PhD)a
a Department of Cardiac Surgery, Heart Center Leipzig, University of Leipzig, Leipzig, Germany
b Division of Cardiac, Thoracic and Vascular Surgery, Columbia University Medical Center, New York, NY, USA
c Center for Clinical Trials (KKS), University of Leipzig, Leipzig, Germany
Introduction
Aortic stenosis (AS) is a progressive disease characterized by a
long asymptomatic period. Once symptoms occur, patient
survival is markedly limited. Progressive pressure overload
imposed on the left ventricle (LV) in the presence of longstanding
AS often leads to LV remodeling and hypertrophy, even in the
absence of symptoms [1]. These structural changes may gradually
cause diastolic and, at a later stage, systolic dysfunctions
[2]. Furthermore, it has been demonstrated that the cardiac
structural and functional alterations are associated not only with
the development of symptoms [3,4], but also with the type of
symptom (i.e. angina, dyspnea, or syncope) [5,6]. However, it has
been never investigated which clinical and echocardiographic
characteristics are associated with the presence of advanced
symptoms in patients with severe AS referred for aortic valve
replacement (AVR). Whether the severity of valve narrowing itself
or the cardiac structural changes secondary to valvular afterload
determines the severity of symptoms is still not well understood.
Hence, we aimed to describe the relationship between the
presence of advanced symptoms and the clinical and echocardio-
graphic characteristics of a cohort of patients with severe AS
referred for AVR.
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A B S T R A C T
Background: Once aortic stenosis (AS) is severe, patients develop symptoms at different stages. Indeed,
symptom status may correlate poorly with the grade of valve narrowing. Multiple pathophysiological
mechanisms, other than valvular load, may explain the link between AS and symptom severity. We
aimed to describe the relationship between the severity of symptoms and the characteristics of a cohort
of patients with severe AS already referred for aortic valve replacement (AVR).
Methods: We analyzed 118 consecutive patients (70 ! 9 years, 55% men) with severe AS referred for AVR.
We identified 84 patients with New York Heart Association (NYHA) I–II, and 34 with NYHA III–IV symptoms.
Clinical and echocardiographic parameters were compared between these two groups. Left ventricular
ejection fraction (LVEF), global longitudinal peak systolic strain (GLPS), NT-pro-B-type natriuretic peptide
(BNP), and high-sensitive troponin T (hs-TNT) were determined at the time of admission.
Results: AS severity was similar between groups. Compared with the NYHA I–II group, patients in NYHA
III–IV group were older and more likely to have comorbidities, worse intracardiac hemodynamics and
more LV damage. Variables independently associated with NYHA III–IV symptomatology were the
absence of sinus rhythm, higher E/e0 ratio, and increased hs-TNT. GLPS showed a good correlation not
only with hs-TNT as a marker of myocardial damage, but also with markers of increased afterload
imposed on LV, being not directly related with advanced symptoms.
Conclusions: Advanced symptoms in patients with severe AS referred for AVR are associated with worse
intracardiac hemodynamics, absence of sinus rhythm, and more myocardial damage. It supports the
concept of transition from adaptive LV remodeling to myocyte death as an important determinant of
symptoms of heart failure.
! 2016 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.
* Corresponding author at: University of Leipzig, Heart Center Leipzig,
Strümpellstraße 39, 04289 Leipzig, Germany. Fax: +49 341 865 1170.
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Methods
Population
Between August 2012 and February 2013, 118 patients
(70 ! 9 years, 55% men) referred to our center with severe AS for
AVR were evaluated by our echocardiographic laboratory and
prospectively enrolled in this study. Severe AS was the principal
indication for surgery, and patients having an associated cardiac valve
lesion more than moderate were excluded. Symptoms related to AS
were recorded by a cardiologist at admission and before echocardio-
graphic evaluation. According to a combination of the Canadian
Cardiovascular Society score (CCS) and the New York Heart
Association (NYHA) functional class, the symptoms were represented
as follows: NYHA-I, no symptoms; NYHA-II, symptoms with
moderate exertion (including CCS II and I); NYHA-III, symptoms
with mild exertion (CCS III); and NYHA-IV, symptoms at rest (CCS IV).
Patients presenting an isolated episode of syncope with moderate
exertion without other symptoms in daily activity were considered to
be at NYHA class II. Afterwards, the whole population was divided
into two groups: 84 with NYHA I–II and 34 with NYHA III–IV
(advanced) symptoms. Within patients in NYHA-I class, the indication
for surgery was assessed by the referring cardiologist, usually by an
abnormal exercise test or the rate of peak transvalvular velocity
progression. Other data collected at the time of admission included
the cardiovascular risk factors, previous history of renal injury
(diagnosed chronic renal failure, history of even mild acute renal
injury in the last 6 months, or rise in the preoperative serum
creatinine), stroke or transient ischemic attack, presence of coronary
artery disease (CAD: stenosis >50% on angiography), N-terminal-pro-
B-type natriuretic peptide (BNP), C-reactive protein (CRP), and high-
sensitive troponin T (hs-TNT). The BNP ratio (the ratio of BNP to the
reference BNP value for age and sex) was also measured. BNP ratio >1
was interpreted as clinical BNP activation as already suggested
[7]. Finally, absence of sinus rhythm was defined as history of
permanent or persistent atrial fibrillation (AF), or presence of AF at
the time of submission.
Echocardiographic study
Commercially available ultrasound machines (Vivid-7 and E9,
General Electric Healthcare, Wauwatosa, WI, USA) equipped with
an M4S or M5S probe were used for all echocardiographic
examinations. For LV and left atrial (LA) chamber quantification,
we followed the recommendations [8]. LA volume (LAV) was
obtained with the biplane area-length technique, and LA area (LAA)
was measured in an apical four-chamber view. LV volumes and
ejection fraction (EF) were calculated using the biplane Simpson
disk method. LV mass was estimated using the linear method with
the formula recommended by the American Society of Echocardi-
ography [9]. Continuous wave Doppler was used to measure the
aortic transvalvular peak velocities; peak and mean gradients were
calculated using the simplified Bernoulli equation, and aortic valve
area (AVA) using the continuity equation. AS severity was graded
according to recommended guidelines [10]. Peak velocities during
early diastole (e0) were obtained at the level of septal mitral
annulus using pulsed wave tissue Doppler. The E/e0 ratio was then
calculated. Mitral annular plane systolic excursion (MAPSE) was
measured in an apical four-chamber view with M-mode beam
positioned on the lateral mitral annulus. In patients with AF,
measurements were averaged from five heart cycles.
Left ventricular strain
Using the two-dimensional speckle-tracking approach, the
global longitudinal myocardial deformation was evaluated as the
average of the segment strains from the apical four-chamber, two-
chamber, and long-axis views. Endocardial borders were traced
with a software tool (AFI: Automated Function Imaging, GE
Healthcare) that automates 2D speckle tracking to measure real-
time deformation of the myocardial wall. After the tracking quality
was verified for each segment, myocardial motion was analyzed by
speckle tracking within the region of interest [11]. In patients with
AF, we recorded apical loops with similar R–R intervals. When not
possible, global longitudinal peak systolic strain (GLPS) was
recorded as missed.
GLPS could be successfully measured in 114 of 118 patients
(97%). Additionally, intraobserver and interobserver variability was
assessed in 20 patients. The intraobserver analysis showed a mean
absolute difference of 0.1% (95% confidence interval, "0.18 to 0.39%)
for GLPS. The interobserver analysis showed a mean absolute
difference of "0.55% (95% CI, "0.98 to "0.12%) for GLPS, with good
intraclass correlation (0.99, 95% CI 0.96–0.99; p < 0.001).
Statistical analysis
Continuous variables are expressed as mean ! SD. Dichotomous
data are presented as percentages. Statistical differences between
groups were assessed using Student’s t-test for continuous variables
or Fisher’s exact test for categorical variables. Multigroup compar-
isons of continuous variables were performed using an analysis of
variance. Continuous data that were not normally distributed (i.e.
BNP, hs-TNT, CRP, and EuroSCORE) are presented as median values
and corresponding interquartile ranges (IQR: 25th and 75th
percentiles), and were analyzed using non-parametric statistical
tests, as the Mann–Whitney test, and their natural logarithms were
used for logistic regression and correlation. Variables associated with
more advanced symptoms were determined with binary logistic
regression analyses. Those with a good correlation and assumed to
have a clinical implication (i.e. age, diabetes, hypertension, and CAD)
were incorporated into the model and selected by a backward
procedure. Two-tailed p-values <0.05 were considered statistically
significant. Analyses were performed using SPSS software (IBM-SPSS
Statistics, Version 20, IBM Corp., New York, NY, USA).
The study was conducted in accordance with the Declaration of
Helsinki and was approved by the local research ethics committee.
Results
Characteristics of the patients
Tables 1 and 2 list the demographic and echocardiographic
characteristics of the study population. In the whole cohort, 16%
(n = 19) of patients were characterized as being in NYHA class I,
and all other patients were symptomatic as follows: 55% (n = 65) in
NYHA class II, 26% (n = 31) in NYHA class III, and 2.5% (n = 3) in
NYHA class IV. A bicuspid aortic valve was observed in 20 patients
(17%). From the total population, 87 patients (74%) had no or mild
mitral valve regurgitation (MR), and 31 (26%) had mild to moderate
MR. The median overall logistic EuroSCORE was 3.7 (IQR: 1.95–
6.5). The indexed AVA was 0.37 ! 0.09 cm2/m2 and LVEF 58 ! 10%.
Surgical characteristics
A total of 68 (57.6%) patients underwent isolated AVR. A
biological prosthesis was inserted in 93% of patients. A coronary
artery bypass graft (CABG) was performed in 21 patients (17.8%)
with no differences between groups. Interestingly, of the 54 patients
presenting with chest pain (angina), only 13 (24%) had a CAD on
angiography, and 12 (22%) received a revascularization (one patient
underwent a surgical AVR with one vessel CAD considered to be
non-revascularizable). A higher rate of concomitant pulmonary vein
R.A. Spampinato et al. / Journal of Cardiology 70 (2017) 41–4742
isolation (21 vs. 7%, p = 0.05) was performed in the NYHA III–IV
group. Moreover, a trans-catheter aortic valve implantation (TAVI)
was also more frequently performed in this group (18 vs. 3.5%,
p = 0.02).
The overall in-hospital mortality was 1.7% (2 of 118 patients),
and tended to be higher in the NYHA III–IV group (5.9% vs. 0%;
p = 0.08).
Functional class and baseline characteristics
Patients with NYHA III–IV were significantly older than NYHA I–II
patients and more likely to have comorbidities such as hypertension,
renal injury, dyslipidemia, diabetes, atrial fibrillation, and CAD. In
addition, NYHA III–IV patients had a higher EuroSCORE and were
more likely to be receiving beta-blockers, statins, and diuretics.
Table 1
Patient characteristics.
Total (n = 118) NYHA I–II (n = 84) NYHA III–IV (n = 34) p-Value
Age, years, mean ! SD 70 ! 9 69 ! 8.8 73 ! 9.5 0.03
Male, n (%) 65 (55) 46 (55) 19 (56) 0.91
Symptoms, n (%)
Chest pain 54 (46) 35 (42) 19 (56) 0.16
Syncope 20 (17) 15 (18) 5 (15) 0.68
Dyspnea 91 (77) 58 (69) 33 (97) 0.001
Comorbidities, n (%)
Hypertension 101 (86) 68 (81) 33 (97) 0.02
Diabetes 26 (22) 14 (17) 12 (35) 0.03
Dyslipidemia 59 (50) 37 (44) 22 (65) 0.04
Smoker 23 (19.5) 18 (21) 5 (15) 0.46
Atrial fibrillation 10 (8.5) 2 (2.4) 8 (23.5) 0.001
Coronary artery diseasea 27 (23) 12 (14) 15 (44) 0.001
Previous cerebral infarction 8 (6.8) 5 (6) 3 (9) 0.69
Previous renal injury 20 (17) 8 (9.5) 12 (35) 0.001
Chronic obstructive pulmonary disease 14 (12) 10 (12) 4 (12) 1.0
Log EuroSCORE, median (IQR) 3.7 (1.95–6.5) 3 (1.72–5.9) 4.8 (3.4–12) 0.002
Treatment, n (%)
Aspirin 63 (53.4) 46 (55) 17 (50) 0.64
Beta-blockers 64 (54) 40 (48) 24 (71) 0.02
ACE-inhibitors 39 (33) 27 (32) 12 (35) 0.74
ARB 29 (25) 20 (24) 9 (26.5) 0.76
Statins 62 (52.5) 39 (46) 23 (68) 0.04
Diuretics 50 (42.5) 26 (31) 24 (71) <0.001
NYHA, New York Heart Association functional class; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker.
Bold values identify a p.
a Coronary stenosis >50% in at least one territory, as depicted by preoperative coronary angiography.
Table 2
Laboratory and echocardiographic indices.
Total (n = 118) NYHA I–II (n = 84) NYHA III–IV (n = 34) p-Value
Echocardiographic indices
EF, % 58 ! 10.2 60 ! 8.3 52 ! 12.4 <0.001
E/e0 16 ! 6.3 14.2 ! 5 20.6 ! 6.7 <0.001
MAPSE, mm 14.4 ! 3.4 15.1 ! 3.2 12.6 ! 3.4 <0.001
GLPS, % "15.4 ! 3.8 "16.4 ! 3 "13 ! 4 <0.001
Stroke volume index, ml/m2 36.9 ! 10 39.2 ! 9.7 31.5 ! 8.9 <0.001
EDVi, ml/m2 43.3 ! 17.5 41.7 ! 16 47 ! 20.3 0.17
ESVi, ml/m2 18.7 ! 11.8 17 ! 9.8 22 ! 15.1 0.04
LAVi, ml/m2 45 ! 14.6 42.5 ! 13 51.2 ! 17 0.003
LAAi, cm2/m2 12.3 ! 2.8 11.8 ! 2.6 13.6 ! 2.9 0.001
Aortic valve area, cm2 0.7 ! 0.16 0.7 ! 0.16 0.66 ! 0.17 0.15
Aortic valve area index, cm2/m2 0.37 ! 0.09 0.37 ! 0.09 0.35 ! 0.08 0.22
Peak aortic velocity, m/s 4.3 ! 0.7 4.35 ! 0.6 4.05 ! 0.9 0.045
Mean aortic pressure gradient, mmHg 50.2 ! 16 51 ! 13.5 47.4 ! 21 0.23
Trans-tricuspidal gradient, mmHg 34.5 ! 11 31.3 ! 6.6 41 ! 14.7 <0.001
Mass index, g/m2 145 ! 42.7 143 ! 38 148 ! 50 0.52
Posterior wall diastolic thickness, mm 13 ! 2 12.8 ! 2 13.4 ! 2.4 0.15
Zva, mmHg/ml m2 5.9 ! 1.7 5.6 ! 1.4 6.5 ! 2.2 0.01
Laboratory parameters
BNP, ng/L, median (IQR) 559 (278–1654) 399 (215–1074) 1512 (677–6179) <0.001
Activated BNP, n (%) 81 (68.6) 52 (61.9) 29 (85.3) 0.016
hs-TNT, ng/L, median (IQR) 12 (9–18) 11 (8–16) 20 (10–59.5) <0.001
Positive hs-TNT, n (%) 49 (41.5) 29 (34.5) 20 (58.8) 0.02
CRP, mg/dl, median (IQR) 0.2 (0.1–0.3) 0.2 (0.1–0.2) 0.35 (0.18–0.9) 0.001
Creatinine, mg/dl 1.0 ! 0.34 0.95 ! 0.3 1.14 ! 0.4 0.003
Glucose, mg/dl 119 ! 39 117 ! 33 124 ! 51 0.36
NYHA, New York Heart Association functional class; EF, left ventricular ejection fraction; E/e0 , E/e0 ratio from the medial mitral annulus; MAPSE, mitral annular plane
systolic excursion; GLPS, global longitudinal peak systolic strain; EDVi, LV end-diastolic volume index; ESVi, LV end-systolic volume index; LAVi, left atrial volume index;
LAAi, left atrial area index; Zva, valvulo-arterial impedance; BNP, pro-B-type natriuretic peptide; Activated BNP, BNP ratio >1; hs-TNT, high-sensitive troponin T; Positive
hs-TNT, TNT >14 ng/L; CRP, C-reactive protein. Unless otherwise specified, values are expressed as mean ! SD.
Bold values identify a p.
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Interestingly, both patient groups had similar AS severity, but
those with NYHA III–IV had a higher valvulo-arterial load (Zva)
with worse hemodynamics (i.e. higher E/e0 ratio, pulmonary artery
pressure, and LA dimensions) and worse LVEF and GLPS values. In
addition, NYHA III–IV patients had significantly higher creatinine,
BNP, and hs-TNT levels. Table 3 shows the correlations with
advanced NYHA class, and Table 4 the multivariable logistic
regression analysis, revealing that absence of sinus rhythm, E/e0
ratio, and hs-TNT were risk-adjusted variables associated with
more advanced symptoms, even after adjustment for CAD.
Left ventricular function, biomarkers and NYHA functional class
In the whole population, there were three times more patients
with LV involvement detected by GLPS (GLPS worse than "16%)
than by using the classical LVEF definition of LV dysfunction (i.e.
LVEF <50%). The difference was more pronounced in the NYHA I–II
group (Fig. 1). Of the 114 patients with available GLPS and LVEF
measurements, 96 (84.2%) had a normal LVEF. Interestingly, almost
40% (38 of 96) of these patients already had a reduced GLPS.
Patients with advanced symptoms had worse LVEF and GLPS
values, and higher biomarker levels. Although the differences in
the above variables did not reach statistical significance for most
comparisons of NYHA I vs. II patients, the differences between
NYHA class I and classes III and IV, or between NYHA class II and
classes III and IV were significant in the majority. The indexed AVA
Table 3






History of renal injury 0.311 0.001
Dyslipidemia 0.187 0.04
Coronary artery disease 0.201 0.03




log BNPa 0.459 <0.001
BNP ratio§ 0.392 <0.001
log hs-TNTa 0.461 <0.001
log CRPa 0.270 0.004
Hematocrit "0.227 0.02
Creatinine 0.269 0.003
Log EuroSCORE 0.338 <0.001
Peak aortic velocity "0.186 0.045
Mean aortic pressure gradient "0.111 0.23
Aortic valve area "0.135 0.15
Valvulo-arterial impedance (Zva) 0.232 0.01
Trans-tricuspidal gradient 0.419 <0.001
LAAi 0.305 0.001
LAVi 0.272 0.003
LV mass index 0.059 0.52
ESVi 0.193 0.04
EDVi 0.139 0.13
Stroke volume S0.361 <0.001
LVEF S0.339 <0.001
GLPS 0.403 <0.001
E/e0 ratio 0.464 <0.001
MAPSE S0.329 <0.001
ACE, angiotensin-converting enzyme; BNP, B-type natriuretic peptide; hs-TNT,
high-sensitive troponin T; CRP, C-reactive protein; LAAi, left atrial area index;
LAVi, left atrial volume index; LV, left ventricular; ESVi, LV end-systolic volume
index; EDVi, LV end-diastolic volume index; LVEF, left ventricular ejection
fraction; GLPS, global longitudinal peak systolic strain; E/e0 , E/e0 ratio from the
medial mitral annulus; MAPSE, mitral annular plane systolic excursion.
Bold values identify a correlation coefficient >0.300.
a Natural logarithm; r Pearson (§ or Spearman) correlation coefficient.
Fig. 1. Patients with severe aortic stenosis referred for surgery. Association between
left ventricular damage, as assessed by GLPS worse than "16% and ejection fraction
<50%, and NYHA functional class. GLPS, global longitudinal peak systolic strain;
LVEF, left ventricular ejection fraction; NYHA, New York Heart Association.
Table 4
Variables associated with NYHA III–IV functional class.
Variables Univariate Multivariable analysis
Odds ratio (95% CI) p-Value Odds ratio (95% CI) p-Value
Age 1.06 (1.05–1.10) 0.031 – –
Male sex 0.96 (0.43–2.13) 0.913 – –
Diabetes mellitus 0.37 (0.15–0.90) 0.045 – –
Hypertension 0.13 (0.02–1.01) 0.051 – –
Coronary artery disease 0.21 (0.09–0.53) 0.001 – –
Lack of sinus rhythm 12.6 (2.52–63.18) 0.002 11.49 (1.90–69.6) 0.008
LVEF 0.93 (0.89–0.97) 0.001 – –
Peak aortic velocity 0.56 (0.31–0.99) 0.048 – –
GLPS 1.30 (1.14–1.48) <0.001 – –
E/e0 ratio 1.19 (1.10–1.29) <0.001 1.15 (1.05–1.25) 0.002
Preoperative MR 0.25 (0.10–0.59) 0.002 – –
log TNTa 23.0 (4.99–105.9) <0.001 12.56 (2.70–58.5) 0.001
log BNPa 8.5 (3.2–22.58) <0.001 – –
Creatinine 5.98 (1.52–23.43) 0.010 – –
NYHA, New York Heart Association functional class; EF, left ventricular ejection fraction; GLPS, global longitudinal peak systolic strain; E/e0 , E/e0 ratio from the medial
mitral annulus; TNT, troponin T; BNP, B-type natriuretic peptide.
Bold values identify a p.
a Natural logarithm. MR, presence of mild to moderate mitral valve regurgitation (more than moderate MR was an exclusion criteria).
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tended to decrease with NYHA class, but did not reach statistical
significance (Fig. 2 and Table 5).
GLPS correlations
GLPS showed a good correlation with other echocardiographic
parameters of LV contractility or systolic function: LVEF (r = "0.64,
p < 0.001), MAPSE (r = "0.46, p < 0.001), and indexed stroke
volume (r = "0.49, p < 0.001); with parameters of left chambers
dilatation: LV end-diastolic volume index (r = 0.40, p < 0.001), LV
end-systolic volume index (r = 0.59, p < 0.001), and LA-volume
(r = 0.44, p < 0.001); and moderately with LV hypertrophy: LV
mass (r = 0.32, p = 0.001); and with parameters related with LV
overload: indexed AVA (r = "0.31, p = 0.001) and Zva (r = 0.35,
Fig. 2. Severe aortic stenosis. Association between NYHA functional class and left ventricular function, biomarkers, and aortic valve area (values are mean ! 95% CI). BNP, B-
type natriuretic peptide; CRP, C-reactive protein; EF, ejection fraction; EOAi, aortic valve effective orifice area index; GLPS, global longitudinal peak systolic strain; hs-TNT, high-
sensitive troponin T; NYHA, New York Heart Association.
Table 5
Left ventricular function, biomarkers, and AS severity in relation with NYHA.
NYHA I§ NYHA II# NYHA III! NYHA IV@ p-Value
EF 62 ! 4!@ 59.5 ! 9@ 54 ! 11.5§@ 36 ! 6.5§#! <0.001
GLPS "17.5 ! 2.5!@ "16 ! 3!@ "13.5 ! 4§# "9.5 ! 4§# <0.001
BNP 379 (215–633)!@ 399 (240–1214)!@ 1044 (662–2999)§# 6667 (6342–7413)§# <0.001
BNP ratio 1.79 (0.97–2.61)@ 3.73 (1.24–6.21)@ 8.68 (3.19–14.18) 23.14 (9.07–37.21)§# 0.002
hs-TNT 14 (8.5–18) 11 (8–15)! 17 (10–55)# 125 (80.5–142) 0.004
CRP 0.2 (0.1–0.2) 0.1 (0.1–0.2)! 0.3 (0.1–0.9)# 0.4 (0.3–1.05) 0.028
EAOi 0.39 ! 0.11 0.37 ! 0.08 0.37 ! 0.09 0.28 ! 0.07 0.27
AS, aortic stenosis; EOAi, aortic valve effective orifice area index (cm2/m2); BNP, pro-B-type natriuretic peptide; BNP ratio, ratio of BNP value to normal BNP range
according age and sex; NYHA, New York Heart Association functional class; EF, left ventricular ejection fraction; GLPS, global longitudinal peak systolic strain; hs-TNT,
high-sensitive troponin T; CRP, C reactive protein. BNP, BNP ratio, hs-TNT, and CRP are medians (IQR). Differences reached statistical significance with: § group ‘‘NYHA I’’,
# group ‘‘NYHA II’’, ! group ‘‘NYHA III’’, and @ group ‘‘NYHA IV’’.
Bold values identify a p.
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p < 0.001), but no significant correlation was found with
transvalvular velocities or gradients. Hemodynamic parameters
were also correlated with GLPS: E/e0 ratio (r = 0.46, p < 0.001) and
trans-tricuspidal gradient (r = 0.49, p < 0.001). Finally, GLPS
showed a good correlation with hs-TNT (r = 0.42, p < 0.001) and
BNP (r = 0.54, p < 0.001).
Discussion
Our study shows the following in patients with severe AS
referred for AVR: (1) advanced symptoms at the time of admission
are not associated with the severity of the AS itself (grade of valve
narrowing), but rather with age, comorbidities, worse intracardiac
hemodynamics, and more LV damage. Variables independently
associated with NYHA III–IV symptoms are the absence of sinus
rhythm, higher E/e0 ratio, and increased hs-TNT; (2) GLPS showed a
good correlation not only with markers of myocardial damage, but
also with markers of increased afterload imposed on LV, being not
independently related to advanced symptoms.
Degenerative AS [2,12] could be viewed as a disease with a
silent phase of sclerosis and calcification of the valve, followed by
progression of AS severity with different grades of LV involvement
(LV overload, remodeling, and later myocardial damage). Once the
AS is classified as severe, patients develop symptoms at different
stages of the disease process. Indeed, within the severe AS
category, symptom status may correlate poorly with the grade of
valve narrowing [6]. Multiple pathophysiological mechanisms,
rather than isolated valvular load, may therefore explain the link
between AS and symptom severity.
We showed that advanced symptoms were not related to the
grade of valve narrowing, but with more LV damage and worse
intracardiac hemodynamics (i.e. E/e0 ratio). Our findings are in
accordance with the results published by Park and colleagues [5],
which demonstrated that symptomatic severe AS patients had
lower cardiac output and higher E/e0 ratio while having a similar
AVA and gradients, when compared to asymptomatic severe AS
patients. Recently, Dahl and colleagues [4] reported that, despite
similar AVA, development of symptoms in severe AS with normal
LV function is associated with concentric remodeling, LV
hypertrophy, impaired diastolic function, and LA dilatation but,
interestingly, not with E/e0 ratio. These results probably reflect that
patients in an earlier stage of AS – with normal LV systolic but
already altered diastolic function – may have normal LV filling
pressures at rest with only intermittent increases during exercise
leading to LA dilatation and symptoms on maximal exertion [13].
Additionally, we found that the absence of sinus rhythm was
independently associated with NYHA III–IV, reflecting the rela-
tionship between increased LV filling pressures, LA remodeling and
dysfunction, with a higher rate of atrial fibrillation, which finally
aggravates the symptoms [14].
We were unable to demonstrate a relationship between GLPS
and severity of symptoms in our multivariable analysis. The groups
of Takeda [15] and Tongue [3] have previously demonstrated that
the long-axis excursion of the LV wall, irrespective of LVEF, is
associated with symptom status in AS. Lancellotti et al. [16]
studied asymptomatic patients with moderate to severe AS and
also found that GLPS worse than "15.9% was a significant predictor
of a combined end point of symptom development, AVR, or death.
Our results and those of previous studies most likely reflect that
GLPS is related with the development of symptoms, but not with
the severity of them, where myocardial loss and worse intracardiac
hemodynamics may play a more important role, which is also
shown to be associated with adverse outcomes [17,18]. Indeed,
GLPS is influenced not only by myocyte contraction, but also by the
composition of the surrounding tissue (i.e. myocardial fibrosis) and
pressure-volume characteristics of the LV [19,20]. In accordance
with this, GLPS showed in our study a good correlation with
different parameters, which are not only markers of myocardial
damage, but also markers of increased afterload imposed on LV.
This suggests that GLPS could be capable to detect an earlier stage
of AS with LV involvement only secondary to pressure overload
with or without mild diffuse subendocardial fibrosis, but before
advanced myocardial injury and heart failure symptoms occur.
Moreover, analyses of multidirectional strain suggested a progres-
sion from subendocardial (i.e. longitudinal strain) to transmural
(i.e. circumferential and eventually radial strain) impairment of
myocardial function in AS patients [21]. In the current study, 40% of
patients with normal LVEF already had LV involvement, defined as
a GLPS worse than "16%. Interestingly, the majority of these
patients were in the NYHA I–II group (26 of 38; 68.5%), which could
be explained maybe because in the NYHA III–IV group the LV
circumferential and radial function involvement could already be
detected by a reduced LVEF (i.e. <50%).
Finally, a positive relationship with more advanced NYHA
functional class was showed for BNP levels and ratio (Table 3 and
Fig. 2), but surprisingly, we did not find an independent association.
Previous studies showed that natriuretic peptides correlate with the
severity of AS [22], and symptomatic patients have significantly
higher levels of BNP than asymptomatic patients with severe AS. In
addition, in this latter group, the BNP levels are associated with the
onset of symptoms [23]. But an overlap of plasma levels of BNP is
observed in patients with NYHA classes I and II. In our population,
we did not find differences between NYHA-I and NYHA-II groups
respective BNP levels. Moreover, in a recent large prospective study,
almost 60% of asymptomatic patients with isolated severe AS and
normal LVEF had already a clinical BNP activation [7]. It could be
argued that BNP is a sensitive marker with elevations also in earlier
stages of the AS with only LV diastolic dysfunction and no or
minimal symptoms. Later, a subsequent release of BNP is joined
with the occurrence of myocardial damage, LV systolic dysfunction,
and advanced symptoms. Indeed, BNP levels have been correlated
to myocardial fibrosis and its surrogate markers (i.e. late gadolini-
um enhancement) [24]. In accordance with this, we found a strong
positive correlation between BNP, hs-TNT, and NYHA classes III–IV
(Fig. 3). This suggests that patients with severe AS and the highest
levels of BNP are highly probable, already symptomatic, and most
likely with advanced symptoms. But in this subset of patients,
Fig. 3. Severe aortic stenosis. Correlation between BNP and hs-TNT in accordance to
NYHA class. Values are represented on a logarithmic scale; r, Pearson correlation
coefficient; BNP, B-type natriuretic peptide; hs-TNT, high-sensitive troponin T;
NYHA, New York Heart Association.
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myocardial damage may play a more important role in the complex
pathophysiology of severe AS and heart failure symptoms on
minimal exertion.
Study limitations
The vast majority of our patients underwent elective opera-
tions, which may have contributed to the relatively small number
of patients with NYHA class IV symptoms. We did not separate
asymptomatic from symptomatic patients in our analysis because
the NYHA class I group was small and also the intention was to
analyze differences between patients with or without advanced
symptoms before AVR.
Intentionally, we did not exclude patients with coronary artery
disease from analysis, with the hypothesis of possible independent
contribution to LV systolic/diastolic dysfunction and thus to
symptoms. Finally, our study was conducted in a single referral
tertiary hospital, and therefore relatively few patients with
isolated severe AS without comorbidities were included. However,
our cohort may well represent the current group of patients with
severe AS who are being referred for AVR.
Conclusions
Our study is the first to demonstrate that the presence of
advanced symptoms in patients with severe AS referred for AVR is
associated with worse intracardiac hemodynamics, absence of
sinus rhythm, and with higher values of hs-TNT as a marker of
myocardial damage. This supports the concept of transition from
adaptive LV remodeling to myocyte death as an important
determinant of symptoms of heart failure.
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Calcific aortic stenosis is the most common form of valvular heart disease in the western 
world, growing up with the aging of the population. It represents a major healthcare 
burden, introducing high healthcare costs because of the associated morbidity. Nowadays, 
there are no medical treatments capable of delaying or halting the progression of the 
disease. So, the only treatment that we have available for these patients is the surgical 
and trans-catheter aortic valve replacement, with excellent results, which can be seen as a 
medical advantage of the last decades. Success, that can be attributed at least in part to a 
proper timing of aortic valve replacement. 
Today, the proportion of patients referred for aortic valve replacement with “advanced” 
symptoms is still relative high. In our study population approximately 29% of patients with 
severe aortic stenosis were referred for aortic valve replacement presenting a NYHA class 




octogenarians [48]. This difference may be related or pronounced due to underestimation 
of symptoms in the elderly sedentary patients [49].   
Now, our study shows that in patients with severe aortic stenosis referred for aortic valve 
replacement: (1) the presence of “advanced” symptoms at the time of admission is not 
associated with the severity of the aortic stenosis itself (grade of valve narrowing), but 
rather with age, comorbidities, worse intracardiac hemodynamics and more LV damage. 
Variables independently associated with NYHA III-IV symptoms are increased high 
sensitive-TNT, higher E/e´ ratio, and the absence of sinus rhythm; and (2) global 
longitudinal peak systolic strain (GLPS) showed a good correlation not only with markers 
of myocardial damage, but also with markers of increased afterload imposed on LV, being 
not independently related with the presence of “advanced” symptoms. 
Interestingly, despite the protective benefits of aortic valve replacement, patients with mid-
wall fibrosis (MWF) depicted by cardiovascular magnetic resonance (CMR) who undergo 
aortic valve replacement are still at higher risk than those without mid-wall fibrosis [50, 51]. 
We now demonstrate the association of advanced symptoms with myocardial damage 
expressed as higher levels of hs-TNT, independently of the presence of coronary artery 
disease. Supporting the concept of referring patients with severe aortic stenosis for aortic 
valve replacement in an early stage of the disease with “minimal” symptoms and “no” 
evidence of LV myocardial damage, avoiding the occurrence of advanced heart failure 
symptoms to prevent postoperative worse outcomes. 
Degenerative aortic stenosis could be viewed as a disease with an initial silent phase of 
endothelial damage and cellular activation with consecutive valvular inflammation and lipid 
deposition, followed by a “propagation phase” of progressive valve sclerosis and 




phase, fibrocalcific aortic valve disease is accompanied with different grades of LV 
involvement: from only LV overload, through concentric LV remodeling with first 
compensatory hypertrophy and later also accompanied myocardial fibrosis, until advanced 
myocardial damage with eccentric remodeling and finally bilateral ventricle involvement 
[32]. In fact, once aortic stenosis is classified as severe, patients develop symptoms at 
different stages of the disease process. Thus, within the severe AS category, symptom 
status correlates poorly with the grade of valve narrowing [46]. Multiple pathophysiological 
mechanisms, rather than isolated valvular load, should therefore explain the link between 
aortic stenosis and symptom severity. 
As expected, we showed that the presence of advanced symptoms was not related with 
the grade of valve narrowing. Contrarily, independently associated variables were worse 
intra-cardiac hemodynamics (i.e. higher E/e´ratio and absence of sinus rhythm) and more 
LV damage (i.e. higher levels of hs-TNT). It has been hypothesized, that the 
pathophysiology of advanced symptoms in aortic stenosis is majorly related to an 
imbalance between the global increase in left ventricle overload, of valvular (i.e. aortic 
stenosis) and/or vascular (i.e. hypertension) origin, and LV reserve [52]. Moreover, the left 
ventricle remodeling might not only be caused by aortic stenosis as such but also by 
associated comorbidities. So, in the course of disease´s progression to severe aortic 
stenosis the “onset” of symptoms depends on the interplay of aortic valve narrowing with 
multiple other linked factors, such as age, gender, and the association with comorbidities 
(i.e. hypertension, diabetes, coronary artery disease, etc.) which ultimately, through 
different levels of activation of complex paracrine and systemic signal pathways, favor or 
not an accelerated left ventricle remodeling with unfavorable effects like fibrosis and 




The precise mechanisms behind the transition from adaptive to maladaptive hypertrophy 
are poorly defined but involve cardiomyocyte death and myocardial fibrosis [40]. 
Summarizing, our study is the first to demonstrate that the presence of advanced 
symptoms in patients with severe aortic stenosis referred for aortic valve replacement is 
associated with worse intracardiac hemodynamics, absence of sinus rhythm, and with 
higher values of hs-TNT as a marker of myocardial damage. Supporting the concept of 
transition from adaptive LV remodeling to myocyte death as an important determinant of 
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